11 Mar, 2014

Spago appoints manager for preclinical development

Dr. Emil Altonen appointed as manager for preclinical developmentEmil Altonen has been appointed as manager for preclinical development at Spago Imaging AB and will also be a part of the management group. Emil has a PhD in microbiology and has been working as a Senior Scientist at Spago since 2009.

For further information contact Andreas Bunge, CEO, SPAGO Imaging AB, +46 708 242525.

SPAGO Imaging conducts research and development in the nanomedicine field with a focus on cancer diagnostics and treatment. The development is based on SPAGO’s two platform technologies, IonXgel and 3PEG.

IonXgel is a unique nanomaterial and the basis for SPAGO’s novel cancer selective MRI contrast agent, SPAGO Pix. SPAGO Pix has the potential to significantly improve cancer diagnosis with MRI (Magnetic Resonance Imaging). This novel contrast agent is designed to visualize smaller soft tissue tumors with an increased specificity, i.e. with fewer false positive results. This could make it possible to provide patients with earlier treatment and avoid unnecessary, stressful and costly diagnostic procedures and treatment. Contrary to the commercially available contrast agents, SPAGO Pix is free from gadolinium. Gadolinium is known to cause NSF, a serious side effect, in certain patients with poor renal function.

The SPAGO Pix portfolio also includes opportunities within cancer selective drug delivery for improved cancer treatment, as well as additional MR imaging indications.

ProtRc is a protein based drug delivery platform. The primary application, ArchaeaPlatin, is a local delivery of Cisplatin for target cancer treatment.

3PEG is a proprietary pegylation platform that can improve critical drug properties of small molecules, peptides and proteins, and provide increased efficacy and reduced side effects, and has therefore a broad clinical application.

Further information can be found on www.spagoimaging.se.

PDF: Spago appoints manager for preclinical development »